Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

    Summary
    EudraCT number
    2016-002763-34
    Trial protocol
    HU   BG   AT   CZ   GB   IS   SE   GR   PT   SK   DE   ES   BE   NL   HR   IT  
    Global end of trial date
    01 Aug 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    14 Jun 2024
    First version publication date
    14 Jun 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    GS-US-419-3896
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02914600
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Galapagos NV
    Sponsor organisation address
    Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
    Public contact
    Galapagos Medical Information, Galapagos NV, medicalinfo@glpg.com
    Scientific contact
    Galapagos Medical Information, Galapagos NV, medicalinfo@glpg.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 Aug 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    01 Aug 2023
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The primary objective of this study is to observe the long-term safety of filgotinib in participants who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
    Protection of trial subjects
    This study was conducted under a US investigational new drug (IND) application and in accordance with recognized international scientific and ethical standards, including but not limited to the International Council for Harmonisation (ICH) guideline for Good Clinical Practice (GCP), and the original principles embodied in the Declaration of Helsinki. These standards are consistent with the requirements of the US Code of Federal Regulations (CFR) Title 21, Part 312 (21CFR312), and the EU Clinical Trials Directive 2001/20/EC as well as other local legislation.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    17 Mar 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Netherlands: 30
    Country: Number of subjects enrolled
    Poland: 108
    Country: Number of subjects enrolled
    Portugal: 9
    Country: Number of subjects enrolled
    Slovakia: 13
    Country: Number of subjects enrolled
    Spain: 24
    Country: Number of subjects enrolled
    Sweden: 2
    Country: Number of subjects enrolled
    United Kingdom: 28
    Country: Number of subjects enrolled
    Croatia: 1
    Country: Number of subjects enrolled
    Austria: 9
    Country: Number of subjects enrolled
    Belgium: 58
    Country: Number of subjects enrolled
    Czechia: 26
    Country: Number of subjects enrolled
    France: 99
    Country: Number of subjects enrolled
    Germany: 71
    Country: Number of subjects enrolled
    Greece: 1
    Country: Number of subjects enrolled
    Hungary: 18
    Country: Number of subjects enrolled
    Ireland: 6
    Country: Number of subjects enrolled
    Italy: 29
    Country: Number of subjects enrolled
    United States: 274
    Country: Number of subjects enrolled
    India: 72
    Country: Number of subjects enrolled
    Ukraine: 52
    Country: Number of subjects enrolled
    Japan: 48
    Country: Number of subjects enrolled
    Canada: 43
    Country: Number of subjects enrolled
    Australia: 40
    Country: Number of subjects enrolled
    Russian Federation: 22
    Country: Number of subjects enrolled
    Israel: 19
    Country: Number of subjects enrolled
    Korea, Democratic People's Republic of: 11
    Country: Number of subjects enrolled
    Sri Lanka: 11
    Country: Number of subjects enrolled
    Switzerland: 10
    Country: Number of subjects enrolled
    Taiwan: 10
    Country: Number of subjects enrolled
    Romania: 9
    Country: Number of subjects enrolled
    Malaysia: 8
    Country: Number of subjects enrolled
    South Africa: 8
    Country: Number of subjects enrolled
    New Zealand: 7
    Country: Number of subjects enrolled
    Georgia: 4
    Country: Number of subjects enrolled
    Hong Kong: 3
    Country: Number of subjects enrolled
    Singapore: 3
    Country: Number of subjects enrolled
    Serbia: 2
    Worldwide total number of subjects
    1188
    EEA total number of subjects
    513
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    1130
    From 65 to 84 years
    58
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Participants were enrolled in 37 countries. Participants with CD, who had completed or met protocol-specified efficacy discontinuation criteria from previous parent studies (GS-US-419-4015 [NCT03046056], GS-US-419-4016 [NCT03077412] or GS-US-419-3895 [GLPG0634-CL-309] [NCT02914561]) were rolled-over to this long-term extension study.

    Pre-assignment
    Screening details
    Sponsor decided not to pursue extension of filgotinib indication for CD, as GS-US-419-3895 did not meet the co-primary endpoint and decided to prematurely terminate the study.

    Period 1
    Period 1 title
    Overall study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator
    Blinding implementation details
    Participants who completed the parent study blinded, received blinded treatment. After un-blinding of the parent study, participants received open-label treatment.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Filgotinib 200 mg
    Arm description
    Participants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg. Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).
    Arm type
    Experimental

    Investigational medicinal product name
    Filgotinib 200 mg
    Investigational medicinal product code
    Other name
    GS-6034, GLPG0634, Jyseleca®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Tablet administered orally once daily.

    Arm title
    Filgotinib 100 mg
    Arm description
    Participants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg. Male participants from the US & Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).
    Arm type
    Experimental

    Investigational medicinal product name
    Filgotinib 100 mg
    Investigational medicinal product code
    Other name
    GS-6034, GLPG0634, Jyseleca®
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Tablet administered orally once daily.

    Arm title
    Placebo
    Arm description
    Participants who received placebo and completed the parent study, continued to receive placebo in this extension study. After un-blinding of the parent study, participants on placebo treatment discontinued study drug and study participation. Treatment was administered orally once a day until un-blinding of the parent study (up to 308 weeks).
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Drug matching tablet administered orally once daily.

    Number of subjects in period 1
    Filgotinib 200 mg Filgotinib 100 mg Placebo
    Started
    945
    119
    124
    Completed
    0
    0
    0
    Not completed
    945
    119
    124
         Adverse event, serious fatal
    -
    1
    1
         Consent withdrawn by subject
    158
    20
    18
         Study Unblinded, participant confirmed on Placebo
    -
    -
    55
         Adverse event, non-fatal
    298
    35
    25
         Death
    3
    -
    -
         Pregnancy
    8
    -
    -
         Lost to follow-up
    10
    4
    -
         Enrolled but not treated
    1
    -
    -
         Investigators discretion
    169
    14
    13
         Sponsors decision
    287
    41
    12
         Non compliance with study drug
    6
    1
    -
         Protocol deviation
    5
    3
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Filgotinib 200 mg
    Reporting group description
    Participants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg. Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).

    Reporting group title
    Filgotinib 100 mg
    Reporting group description
    Participants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg. Male participants from the US & Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).

    Reporting group title
    Placebo
    Reporting group description
    Participants who received placebo and completed the parent study, continued to receive placebo in this extension study. After un-blinding of the parent study, participants on placebo treatment discontinued study drug and study participation. Treatment was administered orally once a day until un-blinding of the parent study (up to 308 weeks).

    Reporting group values
    Filgotinib 200 mg Filgotinib 100 mg Placebo Total
    Number of subjects
    945 119 124 1188
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    39.2 ( 13.60 ) 46.7 ( 13.28 ) 42.3 ( 12.42 ) -
    Gender categorical
    Units: Subjects
        Female
    514 33 56 603
        Male
    431 86 68 585
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    18 5 0 23
        Not Hispanic or Latino
    905 112 123 1140
        Not permitted
    22 2 1 25
    Race
    Units: Subjects
        American Indian or Alaska Native
    1 0 0 1
        Asian
    137 18 23 178
        Native Hawaiian or Other Pacific Islander
    2 0 0 2
        Black or African American
    18 10 3 31
        White
    740 89 96 925
        Other
    6 1 0 7
        Not permitted
    41 1 2 44

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Filgotinib 200 mg
    Reporting group description
    Participants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg. Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).

    Reporting group title
    Filgotinib 100 mg
    Reporting group description
    Participants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg. Male participants from the US & Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).

    Reporting group title
    Placebo
    Reporting group description
    Participants who received placebo and completed the parent study, continued to receive placebo in this extension study. After un-blinding of the parent study, participants on placebo treatment discontinued study drug and study participation. Treatment was administered orally once a day until un-blinding of the parent study (up to 308 weeks).

    Primary: Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Close Top of page
    End point title
    Number of Participants with Treatment Emergent Adverse Events (TEAEs) [1]
    End point description
    An AE was defined as any untoward medical occurrence in a participant administered a study drug, and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: • Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug • Any AEs leading to premature discontinuation of study drug. The Safety Analysis Set (SAF) included all participants who took at least 1 dose of study drug.
    End point type
    Primary
    End point timeframe
    From the First Dose to Week 312
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis was intended to be performed for this endpoint.
    End point values
    Filgotinib 200 mg Filgotinib 100 mg Placebo
    Number of subjects analysed
    944
    119
    124
    Units: participants
    820
    103
    96
    No statistical analyses for this end point

    Secondary: Change from Baseline in Patient Reported Outcomes 2 (PRO2) Scores

    Close Top of page
    End point title
    Change from Baseline in Patient Reported Outcomes 2 (PRO2) Scores
    End point description
    PRO2 was a composite score based on 2 components of the CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3) assessed for 7 days The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were summed over the 7 days prior to each visit. The remaining predictors were noted and weighted to create the total CDAI score ranging from 0-600 with a higher score indicating a worse outcome. Participants from safety analysis set with available data were analysed. Here "99999"signifies that no participants were evaluable for the specified timepoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Week (Wk) 12, Wk 24, Wk 48, Wk 96, Wk 156, Wk 216, Wk 264, and Wk 300
    End point values
    Filgotinib 200 mg Filgotinib 100 mg Placebo
    Number of subjects analysed
    911
    113
    113
    Units: units on a scale
    arithmetic mean (standard deviation)
        Baseline: Liquid/ Soft Stool (n= 911,113,113)
    5.6 ( 3.26 )
    4.0 ( 3.12 )
    2.2 ( 1.92 )
        Change at Wk 12:Liquid/ Soft Stool(n=787,103,103)
    -1.6 ( 2.71 )
    -0.7 ( 2.01 )
    0.2 ( 1.44 )
        Change at Wk 24:Liquid/Soft Stool(n=682,89,89)
    -1.8 ( 2.89 )
    -0.7 ( 2.59 )
    0.1 ( 1.15 )
        Change at Wk 48:Liquid/Soft Stool(n=516,74,81)
    -2.0 ( 3.14 )
    -0.8 ( 2.49 )
    0.0 ( 1.21 )
        Change at Wk 96:Liquid/Soft Stool(n=305,49,53)
    -2.2 ( 3.11 )
    -0.7 ( 2.70 )
    0.4 ( 2.79 )
        Change at Wk 156:Liquid/Soft Stool(n=177,30,26)
    -2.4 ( 3.14 )
    -0.7 ( 3.19 )
    -0.2 ( 1.63 )
        Change at Wk 216:Liquid/Soft Stool(n=82,13,6)
    -2.8 ( 3.17 )
    -1.2 ( 4.10 )
    1.0 ( 1.41 )
        Change at Wk 264:Liquid/Soft Stool(n=20,4,0)
    -2.0 ( 2.86 )
    -4.8 ( 6.18 )
    99999 ( 99999 )
        Change at Wk 300:Liquid/Soft Stool(n=4,0,0)
    0.0 ( 2.71 )
    99999 ( 99999 )
    99999 ( 99999 )
        Baseline: Abdominal Pain(n= 911,113,113)
    1.6 ( 0.91 )
    1.0 ( 0.89 )
    0.7 ( 0.75 )
        Change at Wk 12: Abdominal Pain(n=787,103,103)
    -0.6 ( 0.91 )
    -0.2 ( 0.65 )
    0.0 ( 0.52 )
        Change at Wk 24: Abdominal Pain(n=682,89,89)
    -0.7 ( 0.92 )
    -0.2 ( 0.75 )
    0.0 ( 0.51 )
        Change at Wk 48: Abdominal Pain (n=516,74,81)
    -0.8 ( 0.97 )
    -0.3 ( 0.70 )
    -0.1 ( 0.54 )
        Change at Wk 96: Abdominal Pain (n=305,49,53)
    -0.8 ( 1.00 )
    -0.2 ( 0.73 )
    -0.1 ( 0.55 )
        Change at Wk 156: Abdominal Pain (n=177,30,26)
    -0.8 ( 0.98 )
    -0.2 ( 0.77 )
    0.0 ( 0.57 )
        Change at Wk 216: Abdominal Pain (n=82,13,6)
    -0.9 ( 1.05 )
    -0.5 ( 0.88 )
    0.0 ( 0.00 )
        Change at Wk 264: Abdominal Pain (n=20,4,0)
    -0.8 ( 0.64 )
    -1.3 ( 0.50 )
    99999 ( 99999 )
        Change at Wk 300: Abdominal Pain (n=4,0,0)
    -0.3 ( 0.50 )
    99999 ( 99999 )
    99999 ( 99999 )
    No statistical analyses for this end point

    Secondary: Change from Baseline in CDAI Scores

    Close Top of page
    End point title
    Change from Baseline in CDAI Scores
    End point description
    The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and haematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Participants from safety analysis set with available data were analyzed. Here "99999"signifies that no participants were evaluable for the specified timepoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Wk 12, Wk 24, Wk 48, Wk 96, Wk 156, Wk 216, Wk 264, and Wk 300
    End point values
    Filgotinib 200 mg Filgotinib 100 mg Placebo
    Number of subjects analysed
    897
    110
    110
    Units: units on a scale
    arithmetic mean (standard deviation)
        Baseline (n= 897,110,110)
    280.5 ( 116.58 )
    189.9 ( 112.73 )
    120.4 ( 81.33 )
        Change at Wk 12 (n=710,94,92)
    -86.8 ( 114.02 )
    -29.1 ( 79.84 )
    4.2 ( 53.42 )
        Change at Wk 24(n=608,84,82)
    -98.5 ( 122.68 )
    -30.8 ( 92.92 )
    5.7 ( 51.30 )
        Change at Wk 48 (n=461,69,71)
    -110.2 ( 125.08 )
    -40.9 ( 91.47 )
    0.6 ( 49.32 )
        Change at Wk 96(n=261,46,45)
    -118.6 ( 131.49 )
    -23.3 ( 91.94 )
    11.0 ( 69.29 )
        Change at Wk 156 (n=154,28,24)
    -121.4 ( 132.33 )
    -33.5 ( 99.15 )
    0.3 ( 59.27 )
        Change at Wk 216 (n=65,13,4)
    -137.0 ( 147.14 )
    -57.5 ( 121.12 )
    2.5 ( 37.76 )
        Change at Wk 264 (n=16,4,0)
    -134.8 ( 128.86 )
    -171.5 ( 141.81 )
    99999 ( 99999 )
        Change at Wk 300 (n=4,0,0)
    -32.5 ( 92.99 )
    99999 ( 99999 )
    99999 ( 99999 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the First Dose to Week 312
    Adverse event reporting additional description
    Safety Analysis Set
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    Filgotinib 100 mg
    Reporting group description
    Participants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg. Male participants from the US & Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).

    Reporting group title
    Placebo
    Reporting group description
    Participants who received placebo and completed the parent study, continued to receive placebo in this extension study. After unblinding of the parent study, participants on placebo treatment discontinued study drug and study participation. Treatment was administered orally once a day until unblinding of the parent study.

    Reporting group title
    Filgotinib 200 mg
    Reporting group description
    Participants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg. Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).

    Serious adverse events
    Filgotinib 100 mg Placebo Filgotinib 200 mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    34 / 119 (28.57%)
    20 / 124 (16.13%)
    284 / 944 (30.08%)
         number of deaths (all causes)
    2
    1
    6
         number of deaths resulting from adverse events
    2
    1
    5
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Parathyroid tumour benign
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cervix carcinoma stage 0
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lip and/or oral cavity cancer
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lung neoplasm
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Malignant melanoma stage I
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nasal sinus cancer
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Papillary renal cell carcinoma
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Breast cancer
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Prostate cancer
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Squamous cell carcinoma of skin
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tumour inflammation
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Small cell lung cancer
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Thrombophlebitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Condition aggravated
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Death
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Inflammation
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Oedema
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    4 / 944 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Bartholin's cyst
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Endometriosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Female genital tract fistula
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pelvic fluid collection
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vulvovaginal swelling
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary embolism
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Asthmatic crisis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Asthma
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Acute psychosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Adjustment disorder
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Alcohol abuse
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Alcoholism
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Completed suicide
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    Delusional disorder, unspecified type
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Suicide attempt
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Investigations
    General physical condition abnormal
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Blood creatinine increased
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Fractured sacrum
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Alcohol poisoning
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anastomotic leak
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cervix injury
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Facial bones fracture
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Fracture of penis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal anastomosis complication
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Multiple injuries
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    Patella fracture
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Post-traumatic pain
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rib fracture
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Congenital, familial and genetic disorders
    Developmental hip dysplasia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hydrocele
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Acute coronary syndrome
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Mitral valve incompetence
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Myocardial ischaemia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Myocarditis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Coronary artery stenosis
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure acute
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    Atrial fibrillation
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Sinus tachycardia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Aphasia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Dizziness
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Superior sagittal sinus thrombosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Epilepsy
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Peripheral sensory neuropathy
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psychogenic seizure
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Serotonin syndrome
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Dysarthria
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 119 (0.84%)
    1 / 124 (0.81%)
    5 / 944 (0.53%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    1 / 7
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lymphadenopathy
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vestibular disorder
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Colitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anal stenosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anal fistula
         subjects affected / exposed
    1 / 119 (0.84%)
    1 / 124 (0.81%)
    7 / 944 (0.74%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 11
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anal fissure
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    2 / 119 (1.68%)
    0 / 124 (0.00%)
    17 / 944 (1.80%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    1 / 18
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain lower
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal inflammation
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Food poisoning
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Enterocolitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Enteritis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Duodenitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Dental necrosis
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Dental caries
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Crohn's disease
         subjects affected / exposed
    5 / 119 (4.20%)
    4 / 124 (3.23%)
    101 / 944 (10.70%)
         occurrences causally related to treatment / all
    0 / 6
    0 / 4
    5 / 108
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colonic fistula
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colon dysplasia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Haematochezia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colitis ulcerative
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hiatus hernia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ileal stenosis
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    4 / 944 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pancreatic cyst
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Mechanical ileus
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Large intestine perforation
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Large intestinal ulcer
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Large intestinal stenosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Large intestinal obstruction
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal stenosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    2 / 119 (1.68%)
    0 / 124 (0.00%)
    8 / 944 (0.85%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    2 / 9
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal mucosal tear
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal mass
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal haemorrhage
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal fistula
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Inguinal hernia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Impaired gastric emptying
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Subileus
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    4 / 944 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Small intestinal stenosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Small intestinal perforation
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    9 / 119 (7.56%)
    3 / 124 (2.42%)
    11 / 944 (1.17%)
         occurrences causally related to treatment / all
    1 / 10
    0 / 3
    0 / 14
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Short-bowel syndrome
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rectal perforation
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholangitis sclerosing
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Bile duct stone
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Biliary obstruction
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Portal vein thrombosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Diabetic foot
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Erythema nodosum
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Prurigo
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Renal failure
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Stag horn calculus
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Calculus urinary
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    4 / 944 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Renal colic
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ureteric obstruction
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Endocrine disorders
    Goitre
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthritis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Back pain
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intervertebral disc protrusion
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Joint effusion
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Osteonecrosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rheumatoid arthritis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Campylobacter infection
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Abdominal abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Abscess intestinal
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Abscess limb
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anal abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    15 / 944 (1.59%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    3 / 18
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Appendicitis
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Brain abscess
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    5 / 944 (0.53%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    Cellulitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Clostridium difficile colitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colonic abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Herpes zoster disseminated
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis viral
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal infection
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Herpes ophthalmic
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Herpes zoster
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis cryptosporidial
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Liver abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Mastitis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Perirectal abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pulmonary tuberculosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    5 / 944 (0.53%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    2 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pneumonia haemophilus
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Post procedural infection
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psoas abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Peritonitis
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Salmonellosis
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Sinusitis
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal bacteraemia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal infection
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal sepsis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    Subcutaneous abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tuberculosis
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    0 / 944 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vulval abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rectal abscess
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    1 / 119 (0.84%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Diabetes mellitus inadequate control
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Electrolyte imbalance
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    1 / 944 (0.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypophosphataemia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Malnutrition
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    2 / 944 (0.21%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 2%
    Non-serious adverse events
    Filgotinib 100 mg Placebo Filgotinib 200 mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    89 / 119 (74.79%)
    78 / 124 (62.90%)
    697 / 944 (73.83%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Skin papilloma
         subjects affected / exposed
    3 / 119 (2.52%)
    0 / 124 (0.00%)
    14 / 944 (1.48%)
         occurrences all number
    3
    0
    16
    Vascular disorders
    Hypertension
         subjects affected / exposed
    8 / 119 (6.72%)
    3 / 124 (2.42%)
    40 / 944 (4.24%)
         occurrences all number
    8
    3
    41
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    3 / 119 (2.52%)
    0 / 124 (0.00%)
    65 / 944 (6.89%)
         occurrences all number
    4
    0
    94
    Fatigue
         subjects affected / exposed
    5 / 119 (4.20%)
    4 / 124 (3.23%)
    35 / 944 (3.71%)
         occurrences all number
    6
    6
    40
    Asthenia
         subjects affected / exposed
    1 / 119 (0.84%)
    1 / 124 (0.81%)
    20 / 944 (2.12%)
         occurrences all number
    1
    1
    24
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    2 / 119 (1.68%)
    1 / 124 (0.81%)
    21 / 944 (2.22%)
         occurrences all number
    2
    1
    23
    Dyspnoea
         subjects affected / exposed
    0 / 119 (0.00%)
    1 / 124 (0.81%)
    21 / 944 (2.22%)
         occurrences all number
    0
    1
    23
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    3 / 119 (2.52%)
    3 / 124 (2.42%)
    24 / 944 (2.54%)
         occurrences all number
    3
    3
    26
    Insomnia
         subjects affected / exposed
    2 / 119 (1.68%)
    0 / 124 (0.00%)
    23 / 944 (2.44%)
         occurrences all number
    2
    0
    24
    Depression
         subjects affected / exposed
    3 / 119 (2.52%)
    1 / 124 (0.81%)
    20 / 944 (2.12%)
         occurrences all number
    3
    1
    20
    Investigations
    Mycobacterium tuberculosis complex test positive
         subjects affected / exposed
    0 / 119 (0.00%)
    5 / 124 (4.03%)
    12 / 944 (1.27%)
         occurrences all number
    0
    5
    12
    Weight decreased
         subjects affected / exposed
    1 / 119 (0.84%)
    2 / 124 (1.61%)
    22 / 944 (2.33%)
         occurrences all number
    1
    2
    22
    Injury, poisoning and procedural complications
    Procedural pain
         subjects affected / exposed
    3 / 119 (2.52%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences all number
    3
    0
    4
    Meniscus injury
         subjects affected / exposed
    3 / 119 (2.52%)
    1 / 124 (0.81%)
    2 / 944 (0.21%)
         occurrences all number
    3
    1
    2
    Arthropod bite
         subjects affected / exposed
    3 / 119 (2.52%)
    0 / 124 (0.00%)
    5 / 944 (0.53%)
         occurrences all number
    3
    0
    5
    Nervous system disorders
    Headache
         subjects affected / exposed
    4 / 119 (3.36%)
    11 / 124 (8.87%)
    79 / 944 (8.37%)
         occurrences all number
    5
    12
    95
    Dizziness
         subjects affected / exposed
    1 / 119 (0.84%)
    1 / 124 (0.81%)
    26 / 944 (2.75%)
         occurrences all number
    1
    1
    28
    Blood and lymphatic system disorders
    Lymphopenia
         subjects affected / exposed
    2 / 119 (1.68%)
    1 / 124 (0.81%)
    27 / 944 (2.86%)
         occurrences all number
    3
    1
    34
    Iron deficiency anaemia
         subjects affected / exposed
    0 / 119 (0.00%)
    0 / 124 (0.00%)
    22 / 944 (2.33%)
         occurrences all number
    0
    0
    23
    Anaemia
         subjects affected / exposed
    3 / 119 (2.52%)
    5 / 124 (4.03%)
    61 / 944 (6.46%)
         occurrences all number
    3
    5
    73
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    5 / 119 (4.20%)
    5 / 124 (4.03%)
    21 / 944 (2.22%)
         occurrences all number
    5
    6
    27
    Anal fistula
         subjects affected / exposed
    3 / 119 (2.52%)
    5 / 124 (4.03%)
    24 / 944 (2.54%)
         occurrences all number
    3
    5
    31
    Abdominal pain upper
         subjects affected / exposed
    2 / 119 (1.68%)
    1 / 124 (0.81%)
    24 / 944 (2.54%)
         occurrences all number
    2
    1
    27
    Abdominal pain
         subjects affected / exposed
    15 / 119 (12.61%)
    15 / 124 (12.10%)
    93 / 944 (9.85%)
         occurrences all number
    19
    18
    126
    Abdominal distension
         subjects affected / exposed
    5 / 119 (4.20%)
    0 / 124 (0.00%)
    17 / 944 (1.80%)
         occurrences all number
    5
    0
    19
    Vomiting
         subjects affected / exposed
    3 / 119 (2.52%)
    3 / 124 (2.42%)
    67 / 944 (7.10%)
         occurrences all number
    3
    3
    86
    Rectal haemorrhage
         subjects affected / exposed
    3 / 119 (2.52%)
    1 / 124 (0.81%)
    10 / 944 (1.06%)
         occurrences all number
    3
    1
    12
    Nausea
         subjects affected / exposed
    8 / 119 (6.72%)
    4 / 124 (3.23%)
    74 / 944 (7.84%)
         occurrences all number
    8
    6
    83
    Gastrooesophageal reflux disease
         subjects affected / exposed
    3 / 119 (2.52%)
    1 / 124 (0.81%)
    22 / 944 (2.33%)
         occurrences all number
    3
    1
    24
    Gastritis
         subjects affected / exposed
    3 / 119 (2.52%)
    1 / 124 (0.81%)
    16 / 944 (1.69%)
         occurrences all number
    3
    1
    16
    Dyspepsia
         subjects affected / exposed
    2 / 119 (1.68%)
    3 / 124 (2.42%)
    29 / 944 (3.07%)
         occurrences all number
    2
    3
    31
    Diarrhoea
         subjects affected / exposed
    10 / 119 (8.40%)
    11 / 124 (8.87%)
    54 / 944 (5.72%)
         occurrences all number
    13
    12
    66
    Crohn's disease
         subjects affected / exposed
    26 / 119 (21.85%)
    20 / 124 (16.13%)
    210 / 944 (22.25%)
         occurrences all number
    36
    22
    269
    Hepatobiliary disorders
    Cholelithiasis
         subjects affected / exposed
    3 / 119 (2.52%)
    1 / 124 (0.81%)
    5 / 944 (0.53%)
         occurrences all number
    3
    1
    5
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    7 / 119 (5.88%)
    2 / 124 (1.61%)
    27 / 944 (2.86%)
         occurrences all number
    7
    3
    29
    Dermatitis contact
         subjects affected / exposed
    3 / 119 (2.52%)
    1 / 124 (0.81%)
    2 / 944 (0.21%)
         occurrences all number
    3
    1
    2
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    7 / 119 (5.88%)
    2 / 124 (1.61%)
    11 / 944 (1.17%)
         occurrences all number
    9
    2
    11
    Musculoskeletal and connective tissue disorders
    Muscle spasms
         subjects affected / exposed
    4 / 119 (3.36%)
    1 / 124 (0.81%)
    15 / 944 (1.59%)
         occurrences all number
    4
    1
    18
    Intervertebral disc protrusion
         subjects affected / exposed
    3 / 119 (2.52%)
    0 / 124 (0.00%)
    4 / 944 (0.42%)
         occurrences all number
    3
    0
    4
    Back pain
         subjects affected / exposed
    4 / 119 (3.36%)
    1 / 124 (0.81%)
    43 / 944 (4.56%)
         occurrences all number
    5
    3
    53
    Arthralgia
         subjects affected / exposed
    15 / 119 (12.61%)
    1 / 124 (0.81%)
    82 / 944 (8.69%)
         occurrences all number
    24
    3
    103
    Infections and infestations
    Urinary tract infection
         subjects affected / exposed
    8 / 119 (6.72%)
    1 / 124 (0.81%)
    57 / 944 (6.04%)
         occurrences all number
    14
    1
    82
    Upper respiratory tract infection
         subjects affected / exposed
    8 / 119 (6.72%)
    3 / 124 (2.42%)
    57 / 944 (6.04%)
         occurrences all number
    9
    4
    84
    Sinusitis
         subjects affected / exposed
    7 / 119 (5.88%)
    0 / 124 (0.00%)
    30 / 944 (3.18%)
         occurrences all number
    9
    0
    35
    Pharyngitis
         subjects affected / exposed
    1 / 119 (0.84%)
    3 / 124 (2.42%)
    18 / 944 (1.91%)
         occurrences all number
    1
    3
    22
    Oral herpes
         subjects affected / exposed
    3 / 119 (2.52%)
    0 / 124 (0.00%)
    14 / 944 (1.48%)
         occurrences all number
    4
    0
    19
    Anal abscess
         subjects affected / exposed
    3 / 119 (2.52%)
    2 / 124 (1.61%)
    16 / 944 (1.69%)
         occurrences all number
    3
    2
    22
    Bronchitis
         subjects affected / exposed
    5 / 119 (4.20%)
    2 / 124 (1.61%)
    30 / 944 (3.18%)
         occurrences all number
    5
    4
    37
    COVID-19
         subjects affected / exposed
    17 / 119 (14.29%)
    9 / 124 (7.26%)
    127 / 944 (13.45%)
         occurrences all number
    17
    10
    139
    Gastroenteritis
         subjects affected / exposed
    4 / 119 (3.36%)
    1 / 124 (0.81%)
    26 / 944 (2.75%)
         occurrences all number
    5
    1
    29
    Herpes zoster
         subjects affected / exposed
    1 / 119 (0.84%)
    1 / 124 (0.81%)
    22 / 944 (2.33%)
         occurrences all number
    1
    1
    22
    Influenza
         subjects affected / exposed
    4 / 119 (3.36%)
    4 / 124 (3.23%)
    27 / 944 (2.86%)
         occurrences all number
    5
    6
    31
    Latent tuberculosis
         subjects affected / exposed
    2 / 119 (1.68%)
    4 / 124 (3.23%)
    14 / 944 (1.48%)
         occurrences all number
    2
    4
    14
    Nasopharyngitis
         subjects affected / exposed
    13 / 119 (10.92%)
    6 / 124 (4.84%)
    81 / 944 (8.58%)
         occurrences all number
    21
    6
    101
    Metabolism and nutrition disorders
    Folate deficiency
         subjects affected / exposed
    3 / 119 (2.52%)
    0 / 124 (0.00%)
    13 / 944 (1.38%)
         occurrences all number
    5
    0
    14
    Hyperlipidaemia
         subjects affected / exposed
    4 / 119 (3.36%)
    0 / 124 (0.00%)
    3 / 944 (0.32%)
         occurrences all number
    4
    0
    3
    Hypokalaemia
         subjects affected / exposed
    3 / 119 (2.52%)
    2 / 124 (1.61%)
    22 / 944 (2.33%)
         occurrences all number
    4
    2
    24
    Hypophosphataemia
         subjects affected / exposed
    1 / 119 (0.84%)
    1 / 124 (0.81%)
    30 / 944 (3.18%)
         occurrences all number
    1
    1
    35
    Iron deficiency
         subjects affected / exposed
    1 / 119 (0.84%)
    2 / 124 (1.61%)
    21 / 944 (2.22%)
         occurrences all number
    1
    2
    23

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    07 Sep 2016
    Amendment 1: Updated Study Procedures Table and footnotes to reflect changes made to weekly visits assessments/procedures in the protocol. Protocol GS-US-419-3896 title changed from Open-Label to Long-Term Extension study.
    11 Nov 2016
    Amendment 2: Updated Study Procedures Table to reflect changes made to the study visit assessments/procedures in the protocol.
    15 Jun 2017
    Amendment 3: Updates were made in response to the South Korean Ministry of Food and Drug Safety request for the use of 200 mg in males in Korea to be limited to male subjects who had failed 2 classes of biologic therapies (any tumor necrosis factor-alpha [TNFα] antagonist and vedolizumab). Updated sections with emerging relevant clinical and pipeline data, and ensured consistency with Investigator Brochure (IB) Ed 12. Updated Study Procedures Table to reflect changes made to the study visit assessments/procedures in the protocol.
    08 Mar 2018
    Amendment 4: Clarification on inclusion/exclusion criteria including those surrounding hepatitis and tuberculosis (TB), clarified Day 1 visit procedures and provided additional flexibility for enhanced safety monitoring (suggested infectious workups for disease worsening). Updated the department name from Drug Safety and Public Health (DSPH) to Pharmacovigilance & Epidemiology (PVE) Updated the Study Procedures Table and footnotes to reflect changes made to the study visit assessments/procedures in the protocol.
    09 Nov 2018
    Amendment 5: To allow study-wide unblinding of GSUS- 419-3896 after the parent studies (GSUS- 419-4015, GS-US-419-4016 and GSUS- 419-3895) were unblinded. Inclusion criterion # 2 was amended to include a comprehensive list of the Gilead-sponsored Crohn’s disease (CD) parent studies eligible for roll-over into this long-term extension (LTE) study.
    17 Apr 2019
    Amendment 5.1: Updated to allow for continuation of concomitant vedolizumab use in subjects who were previously enrolled in study GS-US-419-4016.
    05 Sep 2019
    Amendment 6: Updated duration of treatment to 432 weeks, or until filgotinib becomes commercially available, whichever comes first, to ensure continued access to filgotinib in subjects who have completed the parent study (GS-US-419-3896). Amended study drug interruption or discontinuation criteria to reflect that subjects with newly positive QuantiFERON® TB test (or centrally reported equivalent assay) are now considered for study drug interruption instead of permanent discontinuation.
    23 Mar 2020
    Amendment 7: Updated study unblinding language to clarify the unblinding process and to allow subject unblinding once the corresponding parent study (GS-US-419-4015, GS-US-419-4016, or GS-US-419-3895) was unblinded. Updated study drug interruption criteria to allow the investigator to make the assessment of active or latent TB infection based on subject’s individual risk factors and further evaluations per standard of care upon seroconversion or sequential indeterminate QuantiFERON® TB tests. Changes were implemented at the request of the United States Food and Drug Administration (US FDA) regarding new safety information of other Janus kinase (JAK) inhibitors on the potential risk of thromboembolic events. A statement was added to clarify the procedures to be followed if the Data Monitoring Committee (DMC) recommended stopping the study due to lack of efficacy.
    02 Dec 2021
    Amendment 8: Changed sponsorship from Gilead Sciences, Inc. to Galapagos NV. The Galapagos study number (GLPG0634-CL-310) was added.
    23 Nov 2022
    Amendment 9: The duration of treatment and end of study were adapted due to the limited number of subjects expected to continue after 31 January 2025 and to allow subjects from other filgotinib treatment studies for CD to be enrolled into this study. Dose interruption criteria regarding renal impairment and lymphopenia were added to align with the IB Edition 17, 15 Jul 2022. The length of time women of childbearing potential should use effective contraception after cessation of filgotinib treatment was changed to align with the post-treatment visit. The requirements for male condom use and reporting of pregnancies in female partners were removed to align with the IB Edition 17, 15 Jul 2022. Monthly pregnancy testing in clinic was changed to allow at home testing for subjects outside the US to reduce the burden on subjects.

    Interruptions (globally)

    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    06 Apr 2023
    After analyzing all available data from the DIVERSITY 1 and DIVERSITY LTE studies, the sponsor decided not to pursue extension of the filgotinib indication for CD and decided to terminate the DIVERSITY LTE study.
    -

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 08:22:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA